Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interferon-induced GTP-binding protein Mx2 (MX2) is a large dynamin-like GTPase induced by type I interferons (IFN-α/β), present in both nuclear and cytoplasmic forms, and primarily acts as a restriction factor against HIV-1 and some other viruses. MX2 binds the viral capsid after reverse transcription but before nuclear import and proviral integration, preventing successful infection by blocking nuclear trafficking of the viral genome, particularly in HIV-1; N-terminal domains and interactions with nuclear pore components are crucial for this activity. Its antiviral spectrum includes several herpesviruses (where GTPase function is required for activity) and possible inhibitory roles in hepatitis B virus. While MX2 is not itself a direct therapeutic target, it represents a key node in the innate immune response, and its upregulation by interferons underlies much of its biological significance.
Not directly targeted by drugs, but mechanism relates to enzyme-mediated hydrolysis of GTP and oligomerization to restrict viral nuclear import. The effect of interferon, an established therapeutic, is to induce MX2 expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interferon-induced GTP-binding protein Mx2 (MX2).